6990 — Sichuan Kelun-Biotech Biopharmaceutical Co Cashflow Statement
0.000.00%
- HK$68.73bn
- HK$65.59bn
- CNY1.93bn
Annual cashflow statement for Sichuan Kelun-Biotech Biopharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -890 | -567 | -468 | -143 |
Depreciation | ||||
Amortisation | ||||
Non-Cash Items | 102 | 195 | 177 | 103 |
Unusual Items | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | 279 | 34.5 | 276 | -481 |
Change in Accounts Receivable | ||||
Change in Inventories | ||||
Change in Other Assets | ||||
Change in Accounts Payable | ||||
Change in Payable / Accrued Expenses | ||||
Change in Other Liabilities | ||||
Cash from Operating Activities | -486 | -271 | 59.6 | -430 |
Capital Expenditures | -94.7 | -39 | -82.3 | -81.1 |
Purchase of Fixed Assets | ||||
Purchase / Acquisition of Intangibles | ||||
Other Investing Cash Flow Items | 0.359 | 6.84 | -943 | -741 |
Sale of Fixed Assets | ||||
Sale/Maturity of Investment | ||||
Purchase of Investments | ||||
Cash from Investing Activities | -94.4 | -32.1 | -1,025 | -822 |
Financing Cash Flow Items | -40 | -2.93 | -10 | -2.29 |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 647 | 313 | 2,382 | 1,037 |
Foreign Exchange Effects | ||||
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | 65.6 | 11.2 | 1,436 | -192 |